Bivalirudin in contemporary STEMI treatment

The novel direct thrombin inhibitor bivalirudin is now widely used as an adjunctive therapy in patients undergoing primary PCI for ST elevation myocardial infarction (STEMI). This stems from trial data demonstrating bivalirudin results in lower bleeding rates and better long term survival as compared with the combination of heparin and a GP IIb/IIIa inhibitor. However, […]

Read More…

HORIZON-AMI: 3 year outcomes remain positive

The HORIZONS-AMI trials previously reported a reduction in major bleeding and net adverse clinical events in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) and treated with bivalirudin, as apposed to the use of heparin and a glycoprotein IIb/IIIa inhibitor. ┬áIn addition, if eligible, patients were randomised to receive a paclitaxel-eluting […]

Read More…